Sai Life Sciences Limited, a prominent player in the pharmaceutical industry, has recently received a tax demand order from the Assistant Commissioner, Central Tax, Division-II (Pimpri), Pune-I Commissionerate. The order, issued under Section 74 of the CGST Act, 2017, calls for the payment of Integrated Goods and Services Tax (IGST) amounting to ₹70.16 lakh, along with applicable interest and an equivalent penalty.

Details of the Tax Demand

The tax authorities have raised concerns over two primary issues:

1. Alleged excess availment of Input Tax Credit (ITC)
2. Discrepancies between B2B supply and the Sale/Purchase register updated on the Government Portal

These issues pertain to the financial years 2018-19 to 2021-22, highlighting the importance of maintaining accurate financial records and compliance with tax regulations.

Company's Response

Sai Life Sciences has stated its intention to file an application for rectification of the order. The company appears confident in its position, expressing that it "does not reasonably expect the order to have any material financial impact on the company." This stance suggests that Sai Life Sciences may have grounds to challenge the tax demand or provide clarifications that could potentially reduce or eliminate the liability.

Financial Implications

While the total demand, including tax and penalty, amounts to ₹1.40 crore, it's important to note that this figure represents less than 0.1% of the company's annual revenue, based on publicly available financial data. The relatively small size of the demand in comparison to the company's overall financial position may explain their optimistic outlook regarding the potential impact.

Upcoming Investor Meetings

In a separate announcement, Sai Life Sciences has rescheduled its participation in the Morgan Stanley Twenty Fourth Annual Asia Pacific Summit. The company will now attend one-on-one meetings in Singapore on November 19 and 20, 2025. This engagement with investors suggests that the company maintains an open line of communication with its stakeholders, even in the face of regulatory challenges.

The company has emphasized that no new presentations will be made during these meetings, and they do not intend to discuss any unpublished price-sensitive information.

Sai Life Sciences Limited , a leading Contract Research, Development & Manufacturing Organization (CRDMO), has unveiled plans for a significant expansion of its scientific workforce. The company aims to recruit 200 scientists in November 2025 to meet the growing demand for its Discovery and CMC services.

Recruitment Details

Open Positions and Qualifications

The company is seeking candidates across various scientific functions:

• Process R&D
• Analytical R&D
• Process Engineering
• Biology (in vitro and in vivo)
• DMPK

Desired qualifications include:

• M.Sc. in Organic Chemistry, Life Sciences, Microbiology, Biochemistry, or Biotechnology
• M.Pharm in Pharmacology or related disciplines
• B.E. / M.E. in Chemical Engineering
• Ph.D. in relevant areas

Sai Life Sciences is looking for professionals with 2-14 years of experience in these fields.

Company Expansion and Growth

This recruitment drive is part of Sai Life Sciences' broader expansion strategy. The company has recently announced several growth initiatives:

1. A new CMC Process R&D Center at its Hyderabad campus, set to be completed by September 2026. This facility will:

   • Double the company's Process R&D capacity
   • Add new capabilities in peptide development, oligo intermediates & linkers development, formulation development, and early-phase clinical supplies

2. Launch of a state-of-the-art biology facility at the Hyderabad campus, enhancing the company's Integrated Discovery platform

Siva Chittor, Whole-Time Director and Chief Financial Officer of Sai Life Sciences, emphasized the company's commitment to creating an environment where scientists can excel. He stated, "At Sai, we are continuously building an ecosystem where scientists can do the best work of their careers — solving complex scientific challenges that make a real difference to patients' lives."

Company Overview

Sai Life Sciences has established itself as a significant player in the pharmaceutical and biotech industry:

• Partners with over 300 global innovators, including 18 of the top 20 pharmaceutical companies
• Employs a team of more than 3,400 professionals
• Operates across India, the UK, and the US
• Focuses on accelerating the discovery, development, and commercialization of complex small molecules and emerging modalities

The company's expansion and recruitment efforts underscore its commitment to advancing scientific frontiers and delivering innovative solutions to bring new medicines to patients worldwide.